Balancing Safety Concerns

Explore the role of immunotherapy (IO) rechallenge in the management of esophageal and gastric cancers, weighing safety concerns against the potential clinical benefit of reinitiation. Speakers will review evidence on efficacy, patterns of response, and the risk of recurrent or cumulative immune-related adverse events, and address clinical scenarios in which IO rechallenge may be appropriate. This session will focus on safety considerations surrounding IO rechallenge, covering the incidence and management of recurrent or cumulative immune-related adverse events associated with reinitiation of IO therapy. The discussion will address risk factors, monitoring strategies, and clinical scenarios where rechallenge may pose significant concern, giving participants insight into balancing patient safety with potential therapeutic benefit when considering IO rechallenge.